Title: Developing intranasal inhalation therapies for the treatment of inflammatory and infectious disease of the respiratory system Developing intranasal/inhalation therapies

Abstract:

Title : Developing Intranasal Inhalation therapies for the treatment of inflammatory and infectious disease of the respiratory system Developing intranasal/inhalation therapies for the treatment of inflammatory and infectious disorders of the pulmonary system Disorders affecting the respiratory system including allergies, asthma, and upper respiratory infections are a major course of morbidity and mortality in the US. For years it has been accepted that dysregulation of the nasal alternating turgescence of the inferior turbinates may lead to the development of respiratory disorders. Intranasal therapies seem to provide a great means to deliver treatments to regulate the nasal cycles as well as modulate the mucosal microbiome. In a from molecules to population fashion, the present seminar explores the development of intranasal therapies using candidate substances displaying, anti-inflammatory, antiviral, and microbiome modulating effects. The overarching goal of this research agenda is to develop effective interventions to improve the quality of life of those suffering from Pulmonary Disorders. To this end, a series of basic, translational, applied, and clinical studies have been designed to unveil the therapeutic properties of Xylitol, Chlorphenamine, and grapefruit seed extract from the successful management and treatment of both inflammatory and infectious disorders of the pulmonary system. At the end of the seminar, the audience will be able to: • Recite the importance of the nasal cycle and the nasal microbiome as they relate to pulmonary health • Recall the different phases of the therapeutic pipeline in the context of pulmonary disorders • Identify the therapeutic properties of Xylitol, Chlorphenamine, and grapefruit seed extract • Construct a roadmap of the development of intranasal/inhalation therapies for the treatment of pulmonary disorders.

Biography:

Marcos A. Sanchez-Gonzalez, MD, PhD, He run his own company and he is Chief Scientific Officer Company: Dr. Ferrer BioPhrama Mismi FL